Medical device company from Madrid focused on the design and development of an optically guided radiofrequency ablation system for the treatment of Atrial fibrillation.
Its flagship product, AblaView®, allows the operator to directly assess both the positioning of the ablation catheter on the myocardium and the continuity and transmurality of the ablation. The financing will allow Medlumics to complete the preclinical development of its technology and obtain first in human clinical data.
